Mo F - Search Results

1

Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.

Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray RD, Wong SC, To KF, King AD, Ahuja A, Chan AT. Ma BB, et al. Among authors: mo f. Cancer. 2013 Dec 1;119(23):4145-53. doi: 10.1002/cncr.28327. Epub 2013 Oct 1. Cancer. 2013. PMID: 24114668 Free article. Clinical Trial.

2

Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.

Ma BB, Leungm SF, Hui EP, Mo F, Kwan WH, Zee B, Yuen J, Chan AT. Ma BB, et al. Among authors: mo f. Cancer. 2004 Aug 15;101(4):776-81. doi: 10.1002/cncr.20430. Cancer. 2004. PMID: 15305409 Free article.

3

A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.

Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, Chan AT. Ma B, et al. Among authors: mo f. Cancer Chemother Pharmacol. 2008 Jun;62(1):59-64. doi: 10.1007/s00280-007-0575-8. Epub 2007 Aug 29. Cancer Chemother Pharmacol. 2008. PMID: 17762933 Clinical Trial.

4

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.

Ma BB, Mo F, Tong JH, Wong A, Wong SC, Ho WM, Wu C, Lam PW, Chan KF, Chan TS, Tsui WM, Tsang AK, Fung MN, Chan AT, To KF. Ma BB, et al. Among authors: mo f. Asia Pac J Clin Oncol. 2015 Jun;11(2):160-9. doi: 10.1111/ajco.12342. Epub 2015 Apr 13. Asia Pac J Clin Oncol. 2015. PMID: 25865669

5

Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.

Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT. Hui EP, et al. Among authors: mo f. Cancer. 2015 Aug 15;121(16):2720-9. doi: 10.1002/cncr.29413. Epub 2015 May 6. Cancer. 2015. PMID: 25946469 Free article.

6

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.

Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH. Chan SL, et al. Among authors: mo f. Cancer. 2017 Oct 15;123(20):3977-3985. doi: 10.1002/cncr.30825. Epub 2017 Jun 22. Cancer. 2017. PMID: 28640364 Free article. Clinical Trial.

7

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study.

Hui EP, Ma BBY, Loong HHF, Mo F, Li L, King AD, Wang K, Ahuja AT, Chan CML, Hui CWC, Wong CH, Chan ATC. Hui EP, et al. Among authors: mo f. Clin Cancer Res. 2018 Mar 1;24(5):1030-1037. doi: 10.1158/1078-0432.CCR-17-1667. Epub 2018 Jan 4. Clin Cancer Res. 2018. PMID: 29301831 Clinical Trial.

8

Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.

Ma B, Hui EP, King A, Leung SF, Kam MK, Mo F, Li L, Wang K, Loong H, Wong A, Chan CM, Chan KCA, Wong SCC, Lo YMD, Chan AT. Ma B, et al. Among authors: mo f. Br J Cancer. 2018 Apr;118(8):1051-1055. doi: 10.1038/s41416-018-0026-9. Epub 2018 Mar 20. Br J Cancer. 2018. PMID: 29555989 Free PMC article. Clinical Trial.

9

Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.

Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL. Hui EP, et al. Among authors: mo f. Clin Cancer Res. 2002 Aug;8(8):2595-604. Clin Cancer Res. 2002. PMID: 12171890

10

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Chan AT, et al. Among authors: mo f. J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9. doi: 10.1093/jnci/94.21.1614. J Natl Cancer Inst. 2002. PMID: 12419787

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

978 results

Search Page

Filters